GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRadimed Corp (NAS:IRMD) » Definitions » Return-on-Tangible-Asset

iRadimed (iRadimed) Return-on-Tangible-Asset : 18.91% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is iRadimed Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. iRadimed's annualized Net Income for the quarter that ended in Mar. 2024 was $16.55 Mil. iRadimed's average total tangible assets for the quarter that ended in Mar. 2024 was $87.49 Mil. Therefore, iRadimed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 was 18.91%.

The historical rank and industry rank for iRadimed's Return-on-Tangible-Asset or its related term are showing as below:

IRMD' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.34   Med: 15.12   Max: 25.92
Current: 21.73

During the past 12 years, iRadimed's highest Return-on-Tangible-Asset was 25.92%. The lowest was 1.34%. And the median was 15.12%.

IRMD's Return-on-Tangible-Asset is ranked better than
96.75% of 861 companies
in the Medical Devices & Instruments industry
Industry Median: -2.68 vs IRMD: 21.73

iRadimed Return-on-Tangible-Asset Historical Data

The historical data trend for iRadimed's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRadimed Return-on-Tangible-Asset Chart

iRadimed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.97 2.01 12.28 15.53 19.87

iRadimed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.37 21.93 24.71 20.80 18.91

Competitive Comparison of iRadimed's Return-on-Tangible-Asset

For the Medical Devices subindustry, iRadimed's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRadimed's Return-on-Tangible-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRadimed's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where iRadimed's Return-on-Tangible-Asset falls into.



iRadimed Return-on-Tangible-Asset Calculation

iRadimed's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=17.193/( (83.445+89.637)/ 2 )
=17.193/86.541
=19.87 %

iRadimed's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2024 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=16.548/( (89.637+85.344)/ 2 )
=16.548/87.4905
=18.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2024) net income data.


iRadimed  (NAS:IRMD) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


iRadimed Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of iRadimed's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


iRadimed (iRadimed) Business Description

Traded in Other Exchanges
Address
1025 Willa Springs Drive, Winter Springs, FL, USA, 32708
iRadimed Corp develops, manufactures, markets and distributes a Magnetic Resonance Imaging (MRI) compatible intravenous (IV) infusion pump system, and MRI compatible patient vital signs monitoring system, and accessories and services relating to them. The company provides a non-magnetic IV infusion pump system which is designed to be safe for use during MRI procedures. The MRI products of the company are sold primarily to hospitals and acute care facilities in the United States and internationally.
Executives
Roger E. Susi director, 10 percent owner, officer: CEO, President, Chairman C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
James B Hawkins director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Anthony Vuoto director
Monty K Allen director
Hilda Frederique Scharen-guivel director 440 PALM ISLAND SE, CLEARWATER BEACH FL 33767
John Glenn officer: Chief Financial Officer 7900 HOPYARD ROAD, APT 210, PLEASANTON CA 94577
Christopher K. Scott officer: CHIEF FINANCIAL OFFICER & SECR C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Brent Johnson officer: Exec. VP. Sales & Marketing 4900 HOPYARD RD, SUITE 210, PLEASITAN CA 94588
Steven M. Nardi officer: VP MANUFACTURING C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Louis S. Waldman officer: CONTROLLER C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
Leslie L Mcdonnell director, officer: Chief Exec Officer & Director 1501 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Francis X. Casey officer: VP OF REG AND QUAL ASSURANCE C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708
John K Mccreery officer: Chief Operating Officer IRADIMED CORP, 1025 WILLA SPRINGS BLVD, WINTER SPRINGS FL 32708
Jonathan Kennedy director INTERSIL CORPORATION, 1001 MURPHY RANCH ROAD, MILPITAS CA 95035
Serge Novovich director C/O IRADIMED CORPORATION, 1025 WILLA SPRINGS DR., WINTER SPRINGS FL 32708

iRadimed (iRadimed) Headlines

From GuruFocus

IRADIMED CORPORATION Announces Preliminary Financial Results for Fourth Quarter 2022

By Stock market mentor Stock market mentor 01-18-2023

RESOURCE CONSULTING GROUP INC Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-19-2023

IRADIMED Names John F. Glenn Chief Financial Officer

By GuruFocusNews GuruFocusNews 06-25-2022

IRADIMED Names John F. Glenn Chief Financial Officer

By GuruFocusNews GuruFocusNews 06-15-2022

IRADIMED Names John F. Glenn Chief Financial Officer

By GuruFocusNews GuruFocusNews 05-26-2022